Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in
http://www.100md.com
《血液学杂志》
the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy
the Department of Medical Oncology, University of Cagliari, Cagliari, Italy
the Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy.
Abstract
Anemia occurs in more than 30% of patients with epithelial ovarian cancer before any surgery. High levels of proinflammatory cytokines and increased oxidative stress may contribute to the development of cancer-related anemia. We assessed a population of previously untreated patients with advanced epithelial ovarian cancer to evaluate whether there was a correlation between hemoglobin (Hb) and parameters of inflammation and oxidative stress, stage of disease, and performance status (PS). In 91 patients with epithelial ovarian cancer and 95 healthy women matched for age, weight, and height, levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines, leptin, reactive oxygen species (ROS), and antioxidant enzymes were assessed at diagnosis before treatment. The correlations between Hb, parameters of inflammation and oxidative stress, stage, and PS were evaluated. Hb levels were lower in patients with advanced epithelial ovarian cancer than in control subjects and inversely related to stage and PS. Hb negatively correlated with CRP, Fbg, interleukin 1 (IL-1), IL-6, tumor necrosis factor (TNF), and ROS, and positively correlated with leptin and glutathione peroxidase (GPx). Multivariate regression analysis showed that stage and IL-6 were independent factors determining Hb values. This evidence suggests that anemia in epithelial ovarian cancer is common and its presence is related to stage of disease and markers of inflammation.
Introduction
Anemia is present in more than 30% of patients with epithelial ovarian cancer at the time of initial presentation. The severity of cancer-related anemia (CRA) has been associated with more aggressive tumors.1 Nevertheless, few studies have focused on the mechanisms of cancer-induced anemia.
CRA is typically normochromic, normocytic with a low reticulocyte count. Bone marrow iron stores are adequate or increased, but iron reutilization is impaired, as shown by normal or increased ferritin levels and low serum iron levels and iron binding capacity.2 In CRA, erythroid progenitor cells respond normally to erythropoietin (ePO), but ePO production is often not optimal for the level of anemia.3 The biologic and hematologic characteristics of CRA are similar to those observed in anemia occurring in chronic inflammatory diseases.4-7
Markers of chronic inflammation, commonly observed in patients with malignancy, are thought to relate to the stage of disease, to low performance status (PS), and to compromised nutritional status and weight loss.8-10 Inflammatory mediators, particularly cytokines (interleukin 6 [IL-6], tumor necrosis factor [TNF], and IL-1) have been recognized to play a key role in inducing anorexia, nausea/vomiting, and the severe energy metabolism disorders occurring in patients with advanced cancer. The release of proinflammatory cytokines in neoplastic patients is often associated with increased production of reactive oxygen species (ROS) (H2O2 and ) either as a component of their immune response or as a consequence of increased metabolism.8,11,12 We have shown that in patients with advanced cancer the inflammatory response is inversely related to leptin levels, a marker of nutritional status.9,10,13 Thus, the presence of inflammation in patients with cancer may account for profound physiologic changes, including those metabolic changes resulting in cachexia and, possibly, anemia.
Several in vitro and in vivo studies demonstrated that high levels of proinflammatory cytokines and increased oxidative stress contribute both to the development of anemia and to the resistance to recombinant human ePO.14 Therefore, we asked, in the absence of blood loss, myelosuppressive therapy, and bone metastases, whether the same inflammatory substances, known for their role in the onset of cachexia syndrome, could account for the development of CRA.
Many studies have shown a correlation between inflammation, elevated circulating cytokines, and anemia in mice and in patients with chronic inflammation or end-stage renal disease,15 but direct evidence for this association in a wide population of patients with cancer is lacking. Accordingly, we assessed a population of previously untreated women with epithelial ovarian carcinoma to determine the relationship of hemoglobin (Hb) and parameters of inflammatory stress, including cytokines and ROS.
Patients and methods
The study, approved by the local ethical Committee and by the Institutional Review Board, was carried out at the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia; and the Department of Obstetrics and Gynecology and Department of Medical Oncology of the University of Cagliari, Cagliari, Italy. The study was performed in accordance with the Declaration of Helsinki. All subjects participated in the study as volunteers, after signing an informed written consent.
In all subjects the body mass index (BMI) was calculated as weight (in kg)/height (in m2), whereas the PS was quantified using the World Health Organization–approved eastern Cooperative Oncology Group (eCOG) PS scale.16 This scale evaluates 3 dimensions of health status simultaneously (activity, work, self-care), and scores range from 0 (fully active) to 5 (dead).
In all subjects a blood sample was obtained from venipuncture of an antecubital vein at 8 AM after overnight fasting. The blood samples were collected in tubes with clot-activating factor and centrifuged immediately after collection, and serum was stored at -20°C until assayed. In each serum sample the levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines (IL-6, IL-1, TNF), IL-2, and leptin were analyzed. ROS and antioxidant enzymes (glutathione peroxidase [GPx], and superoxide dismutase [SOD]) were assessed on fresh heparinized blood samples.
Assessment of Hb, hematologic, and iron parameters (RBC, MCV, MCHC, absolute reticulocyte count, serum iron, and ferritin)
All control subjects and patients with ovarian cancer were subjected to the following analysis: Hb concentration, red blood cell (RBC) count, mean cell volume (MCV), mean cell hemoglobin concentration (MCHC), reticulocyte count (percentage and absolute number), concentration of serum iron, and ferritin. Red blood cell count and reticulocyte analysis were undertaken using our routine blood counting analyser (Coulter Gen-S; Beckman Coulter, Fullerton, CA).
All laboratory examinations were performed locally according to good clinical practice. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.
Assessment of CRP and Fbg
Routine laboratory analysis of CRP and Fbg concentration was carried out. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.
Serum levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and leptin.
Proinflammatory cytokines (IL-1, IL-6, and TNF) were detected by a "sandwich" enzyme-linked immunosorbent assay (eLISA) test (Biosource europe SA, Nivelles, Belgium, for IL-6 and TNF; Immunotech SA, Marseille, France for IL-1) using monoclonal antibodies for 2 different epitopes of the cytokine molecule. The absorbance of the sample at 450 nm for IL-6 and TNF and at 405 nm for IL-1 was measured with a spectrophotometer (Sirio; Seac, Florence, Italy). A standard curve was prepared by plotting the absorbance value of the standards versus corresponding concentrations. The concentration of the cytokine in the sample was determined by extrapolating from the standard curve. Intra-assay variations were 3% for IL-6 and 6% for TNF and IL-1. Interassay variations were 7% for TNF, 8% for IL-6, and 7% for IL-1. The results were expressed in picogram per milliliter. Serum levels of leptin were measured by a double-antibody "sandwich" eLISA test (DRG Instruments, Marburg, Germany) by using a monoclonal antibody specific for human leptin. The absorbance was measured at 450 ± 10 nm in a plate reader. The intra-assay and interassay variations were 5% and 7%, respectively. The results were expressed in nanogram per milliliter. More details of the techniques used are described in our previous reports.9,10
Assessment of blood levels of reactive oxygen species (ROS) and antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD)
The ROSs were determined using the FORt test (Callegari, Parma, Italy), which is based on the Fenton reaction. When a 20-μL blood sample was dissolved in an acidic buffer, the hydroperoxides reacted with the transition metal ions liberated from the proteins in the acidic medium and were converted to alkoxy- and peroxy-radicals. The radical species produced by the reaction, which are directly proportional to the quantity of lipid peroxides present in the sample,17,18 interact with an additive (phenylendiamine derivative) that forms a radical molecule evaluable by spectrophotometer at 505 nm (Form CR 2000; Callegari). Results are expressed as FORT U (Fort units) whereby 1 FORT U corresponds to 0.26 mg/L H2O2.18
erythrocyte GPx and SOD activity was measured using a commercially available kit (Ransod; Randox Lab, Crumlin, United Kingdom). The results obtained are expressed in unit per liter (U/L) of whole blood (GPx) and in unit per milliliter (U/mL) of whole blood (SOD).8
Statistical analysis
Data are represented as means plus or minus standard deviation unless otherwise stated. The significance of the difference between the mean values of patients with cancer divided according to stage of disease (stages I-II and stages III-IV) and control group was determined using 2-tailed Student t test or its nonparametric equivalent, the Mann-Whitney U test, when appropriate. Correlations between Hb and clinical (stage of disease, eCOG PS, weight, and BMI) and laboratory variables (CRP, Fbg, IL-1, IL-6, TNF, leptin, ROS, SOD, and GPx) were tested using 2-sided Spearman rank correlation analysis, using Bonferroni correction for multiple tests. Significant relationships were then examined by multivariate linear regression analysis against Hb (dependent variable). Results were regarded as significant if P values were .05 or less.
Results
Hb and other hematologic parameters (RBC, MCV, MCHC, reticulocyte count, serum iron, and ferritin)
Among patients with epithelial ovarian cancer, patients at stages III to IV of disease showed significantly lower Hb levels compared with control group subjects (P < .001) and patients at stages I to II (P < .001). In patients at stages I to II of disease, in turn, Hb levels were not significantly different from control subjects (Table 2; Figure 1). As for other hematologic and iron parameters, it is to be noted that patients with stages III to IV epithelial ovarian cancer had a significantly lower RBC and reticulocyte counts, lower MCV, lower serum iron levels, and significantly higher serum ferritin levels in comparison to healthy individuals and patients at stages I to II (Table 2).
CRP and Fbg in patients with epithelial ovarian cancer and control subjects
CRP and Fbg levels were significantly higher in patients with epithelial ovarian cancer at stages III to IV of disease in comparison to the control group subjects (P < .001) and patients at stages I to II of disease (P < .001). In patients at stages I to II of disease, in turn, CRP and Fbg levels were not significantly different from control subjects (Table 3; Figure 2).
Serum levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and leptin in patients with epithelial ovarian cancer and control subjects
Serum levels of IL-1 and TNF were significantly higher in patients with advanced epithelial ovarian cancer (stages III-IV) compared with control subjects (P < .001) and patients with stages I to II disease (P = .007, P < .001, and P = .003, respectively). Patients at stages I to II of disease, in turn, did not show significantly different levels of IL-1 and TNF compared with control subjects. Levels of IL-6 were significantly higher in patients with epithelial ovarian cancer both in stages III to IV and stages I to II compared with control subjects (P < .001, for both) (Table 3; Figure 3). Serum leptin levels were significantly lower in patients with stages III to IV epithelial ovarian cancer in comparison to control subjects (P < .001) and patients in stages I to II (P < .009). In patients with epithelial ovarian cancer at stages I to II of disease, in turn, leptin levels were not significantly different from control subjects (Table 3; Figure 3).
Blood levels of ROS and antioxidant enzymes GPx and SOD in patients with epithelial ovarian cancer and in control subjects
Blood levels of ROS were significantly higher in patients with epithelial ovarian cancer (both stages III-IV and stages I-II) compared with control subjects (P < .001). Blood levels of GPx and SOD were significantly lower in patients with stages III to IV epithelial ovarian cancer compared with control subjects (P < .001, for both) and patients in stages I to II (P < .001 for GPx and P = .028 for SOD). In patients with stages I to II of disease, GPx and SOD were not significantly different from control subjects (Table 3; Figure 4).
Correlation between hemoglobin, clinical parameters (stage of disease and eCOG PS) and serum levels of proinflammatory cytokines, CRP, Fbg, ROS, and antioxidant enzymes (SOD and GPx)
A significant negative relationship was found between Hb levels and stage of disease (r = -0.84, P < .001) and eCOG PS (r = -0.82, P < .001). A significant positive relationship was found between Hb levels and weight (r = 0.36, P = .022) and BMI (r = 0.48, P = .001). As for laboratory variables, a significant negative correlation was found between Hb levels and CRP (r = -0.73, P = < .001), Fbg (r = -0.67, P < .001), IL-1 (r = -0.50, P = .001), IL-6 (r = -0.78, P < .001), TNF (r = -0.52, P = .001), and ROS (r = -0.73, P < .001) levels. A significant positive correlation was found between Hb levels and serum levels of leptin (r = 0.455, P = .001) and blood levels of GPx (r = 0.62, P < .001). SOD levels did not show a significant correlation with Hb levels (r = 0.19, P = .245) (Table 4). Significant relationships were further included in multivariate regression analysis. With regard to Hb (dependent variable), the evaluation revealed that only stage (coefficient = -0.5906, P = .035) and IL-6 levels (coefficient = -0.0230, P = 0.046) were independent factors predicting Hb levels (Table 5). Moreover, we also tested whether IL-6 was a predictive variable of the other proinflammatory markers: single regression analysis showed that IL-6 was significantly positively correlated with IL-1 (P = .020), CRP (P < .001), Fbg (P = .001), and ROS (P < .001) (Figure 5).
Discussion
The study was designed to determine whether those factors that have been demonstrated to play a critical role in the onset of cachexia, weight loss, and impairment of performance status are also involved in the development of anemia. To test this hypothesis, 91 previously untreated patients with epithelial ovarian cancer were evaluated. As expected, Hb levels were lower in patients than in appropriately matched control subjects. Furthermore, as previously shown by Obermair et al,1 Hb concentrations were inversely related to stage of disease and severity of chronic inflammatory status. In our study, advanced epithelial ovarian cancer (stages III-IV) showed anemia similar to anemia of inflammation (also referred to as anemia of chronic disease), which is characterized by normocytic or microcytic iron-refractory anemia, low serum iron, and preserved bone marrow iron.19 The lowest Hb levels associated with the highest concentrations of markers of inflammation, such as proinflammatory cytokines (IL-6, IL-1, TNF), CRP, and Fbg, and with the lowest leptin levels. Statistical analysis confirmed that Hb inversely correlated with stage and eCOG PS, proinflammatory cytokines (IL-6, IL-1, TNF), CRP, Fbg, and ROS but positively correlated with leptin and GPx. By multivariate regression analysis, only stage of disease and IL-6 levels were independent factors in determining Hb levels.
Van der Zee et al20 demonstrated that higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
A central role for IL-6 in the induction of both CRA and the anemia of inflammatory disease has been recently demonstrated. A specific role for IL-6 in the pathogenesis of anemia has been suggested by ershler21 who has found an increased level of IL-6 with advanced age, presumably because of an age-acquired dysregulation, and a corresponding increased prevalence of anemia. Moreover, several researchers22,23 have demonstrated that IL-6 is both necessary and sufficient for the induction of hepcidin, an iron regulatory hormone responsible for inflammation-induced iron disutilization resulting in the anemia associated with acute and chronic infections,24,25 chronic kidney disease,26 and presumably neoplastic disease.27
The pattern of IL-6 and Hb found in our study in patients with ovarian cancer needs to be further evaluated for other types of cancer. In fact, it could be linked with a specific production of IL-6 by ovarian cancer cells and not a marker of inflammation. Higher serum levels of IL-6 have been found in patients with ovarian cancer than in patients with other malignancies,28 and levels have been shown to correlate with extent of disease29 and unfavorable clinical outcome.30 However, in our previously published studies, we demonstrated that tumor-associated mononuclear cells (lymphocytes and monocytes) from neoplastic effusions and peripheral blood were able to produce high amounts of IL-6 and IL-211,31 and that increased IL-6 levels were associated with CRP and aspecific/ineffective immune response.12 As yet it is not clear whether increased IL-6 levels in patients with advanced ovarian cancer are produced by the tumor itself or mainly by host tissues.
Of note, in the current study we demonstrated a significant positive correlation between IL-6 and other markers of inflammation and oxidative stress (IL-1, CRP, Fbg, and ROS). Thus, high serum levels of IL-6 may be considered an indicator of the inflammatory and pro-oxidative status of patients with epithelial ovarian cancer.
The study did not demonstrate the mechanism through which the high levels of inflammatory mediators could induce CRA. However, several studies, in addition to those cited earlier, showed that proinflammatory cytokines blunt ePO response to anemia and impair erythroid colony formation in response to ePO.32-34 Additionally, proinflammatory cytokines IL-1, IL-6, TNF, and the acute-phase proteins impair iron metabolism, inhibiting the reticuloendothelial iron stores with low iron circulating levels.35-37 Disorder in iron reutilization characterizes also CRA.38
The presence of proinflammatory cytokines in patients with neoplasms has been associated with increased production of ROS (H2O2 and ) either as a reflection of inflammation or as a consequence of their metabolic effects.8,11,12 As shown by our previous8,39 and current study, in patients with advanced ovarian cancer the presence of chronic inflammation is tightly correlated with markers of oxidative stress. Several studies demonstrated that ROSs are capable of inhibiting the production of ePO from kidney tissue.40
The lower leptin levels found in our patients with advanced ovarian cancer may be the consequence of cancer-related nutritional inadequacy and impaired energy metabolism or the direct result of high levels of IL-6 or the other cytokines.9,10 Takeda et al41 hypothesized that nutritional status, probably through leptin action, may affect erythropoiesis and demonstrated that BMI and leptin were inversely correlated with the recombinant human ePO (rHuePO) dose required in patients receiving hemodialysis. Indeed, in vitro studies have suggested that leptin plays a role in enhancing erythropoiesis,42 but, certainly, this hypothesis needs more definitive analysis.
The results we have presented suggest that anemia in patients with epithelial ovarian cancer is, at least in part, the consequence of cancer-related chronic inflammation. Cancer-related anemia must be recognized as a constitutional feature of patients with advanced neoplasms and not necessarily as just a consequence of antineoplastic treatments. Indeed, it has been widely demonstrated that CRA is associated with poor response to treatment and decreased survival,43 and with a decline in energy and activity levels, quality of life, and cognitive functions.44 An increased understanding of the pathogenesis of CRA may help identify the most appropriate treatment strategies.22,45
Footnotes
Prepublished online as Blood First edition Paper, March 17, 2005; DOI 10.1182/blood-2005-01-0160.
Supported by Associazione sarda per la ricerca in oncologia ginecologica ONLUS.
A.M. designed the research, performed the research, analyzed the data, and wrote the paper; C.M. designed the research, performed the research, contributed vital new reagents or analytical tools, analyzed the data, and wrote the paper; D.M., M.C.M., M.R.L., and G.G. performed the research, contributed to patient enrollment and assessment, and collected the data; R.S. performed the research and contributed to the analytical tools; and G.B.M. and G.M. contributed to the design of the research and wrote the paper.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
References
Obermair A, Handisurya A, Kaider A, et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;15: 726-731.
Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28: 1-6.
Nowrousian MR, Kasper C, Oberhoff C. Pathophysiology of cancer-related anemia. In: Smythe J, ed. RHu erythropoietin in Cancer Supportive Treatment. New York, NY: Marcel Dekker; 1996: 13-34.
Spivak JK. The blood in systemic disorders. Lancet. 2000;355: 1707-1712.
Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25: 888-895.
Andrews NC. Disorders of iron metabolism. N engl J Med. 1999;341: 1986-1995.
erslev AJ. Anemia of chronic disease. In: Beutler e, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill Professionals; 2000: 481-488.
Mantovani G, Macciò A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002;98: 84-91.
Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78: 554-561.
Mantovani G, Macciò A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med. 2001;79: 406-414.
Mantovani G, Macciò A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 1997;71: 724-731.
Macciò A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69: 248-252.
Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19: 21-26.
Means RT Jr. The anemia of infection. Baillieres Best Pract Res Clin Haematol. 2000;13: 151-162.
Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100: 3776-3781.
Oken MM, Creech RH., Tormey DC, et al. Toxicity and response criteria of the eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.
Alberti A, Bolognini L, Macciantelli D, et al. The radical cation of N, N-Diethyl-para-Phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed. 2000;26: 253-267.
Cornelli U, Terranova R, Luca S, et al. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr. 2001;131: 3208-3211.
Means RT. Hepcidin and anaemia. Blood Rev. 2004;18: 219-225.
van der Zee AG, de Cuyper eM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75: 1004-1009.
ershler WB. Biological interaction of aging and anemia: a focus on cytokines. J Am Geriatr Soc. 2003;51: S18-S21.
Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113: 1251-1253.
Nemeth e, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113: 1271-1276.
Nemeth e, Valore eV, Territo M, et al. Hepcidin: a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101: 2461-2463.
Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11: 251-254.
Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant. 2004;19: 521-524.
Rivera S, Liu L, Nemeth e, Gabayan V, Sorensen Oe, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. Prepublished on October 12, 2004, as DOI 10.1182/blood-2004-08-3375. (Now available as Blood. 2005;105: 1797-1802).
Nash MA, Ferrandina G, Gordinier M, et al. The role of cytokines in both the normal and the malignant ovary. endocr Relat Cancer. 1999;6: 93-107.
Berek JS, Chung C, Kald K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164: 1038-1042.
Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71: 354-356.
Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med. 1995;73: 409-416.
Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13: 32-37.
Kuzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92: 1684-1688.
Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients whit the anemia of cancer. N engl J Med. 1990;322: 1689-1692.
Alvarez-Hernandez X, Liceaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest. 1989;61: 319-322.
Rogers JT. Ferritin translation by interleukin-1 and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996;87: 2525-2537.
Konijn AM, Carmel N, Levy R, et al. Ferritin synthesis in inflammation: mechanisms of increased ferritin synthesis. Br J Hematol. 1981;49: 361-370.
Denz H, Huber P, Landmann R, et al. Association between the activation of macrophages, changes of iron metabolism and the degree of anemia in patients with malignant disorders. eur J Haematol. 1992;48: 244-248.
Mantovani G, Macciò A, Madeddu C, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003;37: 213-223.
Numcke I, Schneider B, Fandrey J, et al. effect of pro- and antioxidative compounds on renal production of erythropoietin. endocrinology. 1999;140: 641-645.
Takeda A, Toda T, Shinohara S, et al. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40: 104-109.
Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A. 1996;93: 14564-14568.
Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol. 2003;23: 837-843.
Tchekmedian NS. Anemia in cancer patients: significance, epidemiology and current therapy. Oncology. 2002;16: 17-24.
Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003;18: 7-22.(Antonio Macciò, Clelia Ma)
the Department of Medical Oncology, University of Cagliari, Cagliari, Italy
the Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy.
Abstract
Anemia occurs in more than 30% of patients with epithelial ovarian cancer before any surgery. High levels of proinflammatory cytokines and increased oxidative stress may contribute to the development of cancer-related anemia. We assessed a population of previously untreated patients with advanced epithelial ovarian cancer to evaluate whether there was a correlation between hemoglobin (Hb) and parameters of inflammation and oxidative stress, stage of disease, and performance status (PS). In 91 patients with epithelial ovarian cancer and 95 healthy women matched for age, weight, and height, levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines, leptin, reactive oxygen species (ROS), and antioxidant enzymes were assessed at diagnosis before treatment. The correlations between Hb, parameters of inflammation and oxidative stress, stage, and PS were evaluated. Hb levels were lower in patients with advanced epithelial ovarian cancer than in control subjects and inversely related to stage and PS. Hb negatively correlated with CRP, Fbg, interleukin 1 (IL-1), IL-6, tumor necrosis factor (TNF), and ROS, and positively correlated with leptin and glutathione peroxidase (GPx). Multivariate regression analysis showed that stage and IL-6 were independent factors determining Hb values. This evidence suggests that anemia in epithelial ovarian cancer is common and its presence is related to stage of disease and markers of inflammation.
Introduction
Anemia is present in more than 30% of patients with epithelial ovarian cancer at the time of initial presentation. The severity of cancer-related anemia (CRA) has been associated with more aggressive tumors.1 Nevertheless, few studies have focused on the mechanisms of cancer-induced anemia.
CRA is typically normochromic, normocytic with a low reticulocyte count. Bone marrow iron stores are adequate or increased, but iron reutilization is impaired, as shown by normal or increased ferritin levels and low serum iron levels and iron binding capacity.2 In CRA, erythroid progenitor cells respond normally to erythropoietin (ePO), but ePO production is often not optimal for the level of anemia.3 The biologic and hematologic characteristics of CRA are similar to those observed in anemia occurring in chronic inflammatory diseases.4-7
Markers of chronic inflammation, commonly observed in patients with malignancy, are thought to relate to the stage of disease, to low performance status (PS), and to compromised nutritional status and weight loss.8-10 Inflammatory mediators, particularly cytokines (interleukin 6 [IL-6], tumor necrosis factor [TNF], and IL-1) have been recognized to play a key role in inducing anorexia, nausea/vomiting, and the severe energy metabolism disorders occurring in patients with advanced cancer. The release of proinflammatory cytokines in neoplastic patients is often associated with increased production of reactive oxygen species (ROS) (H2O2 and ) either as a component of their immune response or as a consequence of increased metabolism.8,11,12 We have shown that in patients with advanced cancer the inflammatory response is inversely related to leptin levels, a marker of nutritional status.9,10,13 Thus, the presence of inflammation in patients with cancer may account for profound physiologic changes, including those metabolic changes resulting in cachexia and, possibly, anemia.
Several in vitro and in vivo studies demonstrated that high levels of proinflammatory cytokines and increased oxidative stress contribute both to the development of anemia and to the resistance to recombinant human ePO.14 Therefore, we asked, in the absence of blood loss, myelosuppressive therapy, and bone metastases, whether the same inflammatory substances, known for their role in the onset of cachexia syndrome, could account for the development of CRA.
Many studies have shown a correlation between inflammation, elevated circulating cytokines, and anemia in mice and in patients with chronic inflammation or end-stage renal disease,15 but direct evidence for this association in a wide population of patients with cancer is lacking. Accordingly, we assessed a population of previously untreated women with epithelial ovarian carcinoma to determine the relationship of hemoglobin (Hb) and parameters of inflammatory stress, including cytokines and ROS.
Patients and methods
The study, approved by the local ethical Committee and by the Institutional Review Board, was carried out at the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia; and the Department of Obstetrics and Gynecology and Department of Medical Oncology of the University of Cagliari, Cagliari, Italy. The study was performed in accordance with the Declaration of Helsinki. All subjects participated in the study as volunteers, after signing an informed written consent.
In all subjects the body mass index (BMI) was calculated as weight (in kg)/height (in m2), whereas the PS was quantified using the World Health Organization–approved eastern Cooperative Oncology Group (eCOG) PS scale.16 This scale evaluates 3 dimensions of health status simultaneously (activity, work, self-care), and scores range from 0 (fully active) to 5 (dead).
In all subjects a blood sample was obtained from venipuncture of an antecubital vein at 8 AM after overnight fasting. The blood samples were collected in tubes with clot-activating factor and centrifuged immediately after collection, and serum was stored at -20°C until assayed. In each serum sample the levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines (IL-6, IL-1, TNF), IL-2, and leptin were analyzed. ROS and antioxidant enzymes (glutathione peroxidase [GPx], and superoxide dismutase [SOD]) were assessed on fresh heparinized blood samples.
Assessment of Hb, hematologic, and iron parameters (RBC, MCV, MCHC, absolute reticulocyte count, serum iron, and ferritin)
All control subjects and patients with ovarian cancer were subjected to the following analysis: Hb concentration, red blood cell (RBC) count, mean cell volume (MCV), mean cell hemoglobin concentration (MCHC), reticulocyte count (percentage and absolute number), concentration of serum iron, and ferritin. Red blood cell count and reticulocyte analysis were undertaken using our routine blood counting analyser (Coulter Gen-S; Beckman Coulter, Fullerton, CA).
All laboratory examinations were performed locally according to good clinical practice. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.
Assessment of CRP and Fbg
Routine laboratory analysis of CRP and Fbg concentration was carried out. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.
Serum levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and leptin.
Proinflammatory cytokines (IL-1, IL-6, and TNF) were detected by a "sandwich" enzyme-linked immunosorbent assay (eLISA) test (Biosource europe SA, Nivelles, Belgium, for IL-6 and TNF; Immunotech SA, Marseille, France for IL-1) using monoclonal antibodies for 2 different epitopes of the cytokine molecule. The absorbance of the sample at 450 nm for IL-6 and TNF and at 405 nm for IL-1 was measured with a spectrophotometer (Sirio; Seac, Florence, Italy). A standard curve was prepared by plotting the absorbance value of the standards versus corresponding concentrations. The concentration of the cytokine in the sample was determined by extrapolating from the standard curve. Intra-assay variations were 3% for IL-6 and 6% for TNF and IL-1. Interassay variations were 7% for TNF, 8% for IL-6, and 7% for IL-1. The results were expressed in picogram per milliliter. Serum levels of leptin were measured by a double-antibody "sandwich" eLISA test (DRG Instruments, Marburg, Germany) by using a monoclonal antibody specific for human leptin. The absorbance was measured at 450 ± 10 nm in a plate reader. The intra-assay and interassay variations were 5% and 7%, respectively. The results were expressed in nanogram per milliliter. More details of the techniques used are described in our previous reports.9,10
Assessment of blood levels of reactive oxygen species (ROS) and antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD)
The ROSs were determined using the FORt test (Callegari, Parma, Italy), which is based on the Fenton reaction. When a 20-μL blood sample was dissolved in an acidic buffer, the hydroperoxides reacted with the transition metal ions liberated from the proteins in the acidic medium and were converted to alkoxy- and peroxy-radicals. The radical species produced by the reaction, which are directly proportional to the quantity of lipid peroxides present in the sample,17,18 interact with an additive (phenylendiamine derivative) that forms a radical molecule evaluable by spectrophotometer at 505 nm (Form CR 2000; Callegari). Results are expressed as FORT U (Fort units) whereby 1 FORT U corresponds to 0.26 mg/L H2O2.18
erythrocyte GPx and SOD activity was measured using a commercially available kit (Ransod; Randox Lab, Crumlin, United Kingdom). The results obtained are expressed in unit per liter (U/L) of whole blood (GPx) and in unit per milliliter (U/mL) of whole blood (SOD).8
Statistical analysis
Data are represented as means plus or minus standard deviation unless otherwise stated. The significance of the difference between the mean values of patients with cancer divided according to stage of disease (stages I-II and stages III-IV) and control group was determined using 2-tailed Student t test or its nonparametric equivalent, the Mann-Whitney U test, when appropriate. Correlations between Hb and clinical (stage of disease, eCOG PS, weight, and BMI) and laboratory variables (CRP, Fbg, IL-1, IL-6, TNF, leptin, ROS, SOD, and GPx) were tested using 2-sided Spearman rank correlation analysis, using Bonferroni correction for multiple tests. Significant relationships were then examined by multivariate linear regression analysis against Hb (dependent variable). Results were regarded as significant if P values were .05 or less.
Results
Hb and other hematologic parameters (RBC, MCV, MCHC, reticulocyte count, serum iron, and ferritin)
Among patients with epithelial ovarian cancer, patients at stages III to IV of disease showed significantly lower Hb levels compared with control group subjects (P < .001) and patients at stages I to II (P < .001). In patients at stages I to II of disease, in turn, Hb levels were not significantly different from control subjects (Table 2; Figure 1). As for other hematologic and iron parameters, it is to be noted that patients with stages III to IV epithelial ovarian cancer had a significantly lower RBC and reticulocyte counts, lower MCV, lower serum iron levels, and significantly higher serum ferritin levels in comparison to healthy individuals and patients at stages I to II (Table 2).
CRP and Fbg in patients with epithelial ovarian cancer and control subjects
CRP and Fbg levels were significantly higher in patients with epithelial ovarian cancer at stages III to IV of disease in comparison to the control group subjects (P < .001) and patients at stages I to II of disease (P < .001). In patients at stages I to II of disease, in turn, CRP and Fbg levels were not significantly different from control subjects (Table 3; Figure 2).
Serum levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and leptin in patients with epithelial ovarian cancer and control subjects
Serum levels of IL-1 and TNF were significantly higher in patients with advanced epithelial ovarian cancer (stages III-IV) compared with control subjects (P < .001) and patients with stages I to II disease (P = .007, P < .001, and P = .003, respectively). Patients at stages I to II of disease, in turn, did not show significantly different levels of IL-1 and TNF compared with control subjects. Levels of IL-6 were significantly higher in patients with epithelial ovarian cancer both in stages III to IV and stages I to II compared with control subjects (P < .001, for both) (Table 3; Figure 3). Serum leptin levels were significantly lower in patients with stages III to IV epithelial ovarian cancer in comparison to control subjects (P < .001) and patients in stages I to II (P < .009). In patients with epithelial ovarian cancer at stages I to II of disease, in turn, leptin levels were not significantly different from control subjects (Table 3; Figure 3).
Blood levels of ROS and antioxidant enzymes GPx and SOD in patients with epithelial ovarian cancer and in control subjects
Blood levels of ROS were significantly higher in patients with epithelial ovarian cancer (both stages III-IV and stages I-II) compared with control subjects (P < .001). Blood levels of GPx and SOD were significantly lower in patients with stages III to IV epithelial ovarian cancer compared with control subjects (P < .001, for both) and patients in stages I to II (P < .001 for GPx and P = .028 for SOD). In patients with stages I to II of disease, GPx and SOD were not significantly different from control subjects (Table 3; Figure 4).
Correlation between hemoglobin, clinical parameters (stage of disease and eCOG PS) and serum levels of proinflammatory cytokines, CRP, Fbg, ROS, and antioxidant enzymes (SOD and GPx)
A significant negative relationship was found between Hb levels and stage of disease (r = -0.84, P < .001) and eCOG PS (r = -0.82, P < .001). A significant positive relationship was found between Hb levels and weight (r = 0.36, P = .022) and BMI (r = 0.48, P = .001). As for laboratory variables, a significant negative correlation was found between Hb levels and CRP (r = -0.73, P = < .001), Fbg (r = -0.67, P < .001), IL-1 (r = -0.50, P = .001), IL-6 (r = -0.78, P < .001), TNF (r = -0.52, P = .001), and ROS (r = -0.73, P < .001) levels. A significant positive correlation was found between Hb levels and serum levels of leptin (r = 0.455, P = .001) and blood levels of GPx (r = 0.62, P < .001). SOD levels did not show a significant correlation with Hb levels (r = 0.19, P = .245) (Table 4). Significant relationships were further included in multivariate regression analysis. With regard to Hb (dependent variable), the evaluation revealed that only stage (coefficient = -0.5906, P = .035) and IL-6 levels (coefficient = -0.0230, P = 0.046) were independent factors predicting Hb levels (Table 5). Moreover, we also tested whether IL-6 was a predictive variable of the other proinflammatory markers: single regression analysis showed that IL-6 was significantly positively correlated with IL-1 (P = .020), CRP (P < .001), Fbg (P = .001), and ROS (P < .001) (Figure 5).
Discussion
The study was designed to determine whether those factors that have been demonstrated to play a critical role in the onset of cachexia, weight loss, and impairment of performance status are also involved in the development of anemia. To test this hypothesis, 91 previously untreated patients with epithelial ovarian cancer were evaluated. As expected, Hb levels were lower in patients than in appropriately matched control subjects. Furthermore, as previously shown by Obermair et al,1 Hb concentrations were inversely related to stage of disease and severity of chronic inflammatory status. In our study, advanced epithelial ovarian cancer (stages III-IV) showed anemia similar to anemia of inflammation (also referred to as anemia of chronic disease), which is characterized by normocytic or microcytic iron-refractory anemia, low serum iron, and preserved bone marrow iron.19 The lowest Hb levels associated with the highest concentrations of markers of inflammation, such as proinflammatory cytokines (IL-6, IL-1, TNF), CRP, and Fbg, and with the lowest leptin levels. Statistical analysis confirmed that Hb inversely correlated with stage and eCOG PS, proinflammatory cytokines (IL-6, IL-1, TNF), CRP, Fbg, and ROS but positively correlated with leptin and GPx. By multivariate regression analysis, only stage of disease and IL-6 levels were independent factors in determining Hb levels.
Van der Zee et al20 demonstrated that higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
A central role for IL-6 in the induction of both CRA and the anemia of inflammatory disease has been recently demonstrated. A specific role for IL-6 in the pathogenesis of anemia has been suggested by ershler21 who has found an increased level of IL-6 with advanced age, presumably because of an age-acquired dysregulation, and a corresponding increased prevalence of anemia. Moreover, several researchers22,23 have demonstrated that IL-6 is both necessary and sufficient for the induction of hepcidin, an iron regulatory hormone responsible for inflammation-induced iron disutilization resulting in the anemia associated with acute and chronic infections,24,25 chronic kidney disease,26 and presumably neoplastic disease.27
The pattern of IL-6 and Hb found in our study in patients with ovarian cancer needs to be further evaluated for other types of cancer. In fact, it could be linked with a specific production of IL-6 by ovarian cancer cells and not a marker of inflammation. Higher serum levels of IL-6 have been found in patients with ovarian cancer than in patients with other malignancies,28 and levels have been shown to correlate with extent of disease29 and unfavorable clinical outcome.30 However, in our previously published studies, we demonstrated that tumor-associated mononuclear cells (lymphocytes and monocytes) from neoplastic effusions and peripheral blood were able to produce high amounts of IL-6 and IL-211,31 and that increased IL-6 levels were associated with CRP and aspecific/ineffective immune response.12 As yet it is not clear whether increased IL-6 levels in patients with advanced ovarian cancer are produced by the tumor itself or mainly by host tissues.
Of note, in the current study we demonstrated a significant positive correlation between IL-6 and other markers of inflammation and oxidative stress (IL-1, CRP, Fbg, and ROS). Thus, high serum levels of IL-6 may be considered an indicator of the inflammatory and pro-oxidative status of patients with epithelial ovarian cancer.
The study did not demonstrate the mechanism through which the high levels of inflammatory mediators could induce CRA. However, several studies, in addition to those cited earlier, showed that proinflammatory cytokines blunt ePO response to anemia and impair erythroid colony formation in response to ePO.32-34 Additionally, proinflammatory cytokines IL-1, IL-6, TNF, and the acute-phase proteins impair iron metabolism, inhibiting the reticuloendothelial iron stores with low iron circulating levels.35-37 Disorder in iron reutilization characterizes also CRA.38
The presence of proinflammatory cytokines in patients with neoplasms has been associated with increased production of ROS (H2O2 and ) either as a reflection of inflammation or as a consequence of their metabolic effects.8,11,12 As shown by our previous8,39 and current study, in patients with advanced ovarian cancer the presence of chronic inflammation is tightly correlated with markers of oxidative stress. Several studies demonstrated that ROSs are capable of inhibiting the production of ePO from kidney tissue.40
The lower leptin levels found in our patients with advanced ovarian cancer may be the consequence of cancer-related nutritional inadequacy and impaired energy metabolism or the direct result of high levels of IL-6 or the other cytokines.9,10 Takeda et al41 hypothesized that nutritional status, probably through leptin action, may affect erythropoiesis and demonstrated that BMI and leptin were inversely correlated with the recombinant human ePO (rHuePO) dose required in patients receiving hemodialysis. Indeed, in vitro studies have suggested that leptin plays a role in enhancing erythropoiesis,42 but, certainly, this hypothesis needs more definitive analysis.
The results we have presented suggest that anemia in patients with epithelial ovarian cancer is, at least in part, the consequence of cancer-related chronic inflammation. Cancer-related anemia must be recognized as a constitutional feature of patients with advanced neoplasms and not necessarily as just a consequence of antineoplastic treatments. Indeed, it has been widely demonstrated that CRA is associated with poor response to treatment and decreased survival,43 and with a decline in energy and activity levels, quality of life, and cognitive functions.44 An increased understanding of the pathogenesis of CRA may help identify the most appropriate treatment strategies.22,45
Footnotes
Prepublished online as Blood First edition Paper, March 17, 2005; DOI 10.1182/blood-2005-01-0160.
Supported by Associazione sarda per la ricerca in oncologia ginecologica ONLUS.
A.M. designed the research, performed the research, analyzed the data, and wrote the paper; C.M. designed the research, performed the research, contributed vital new reagents or analytical tools, analyzed the data, and wrote the paper; D.M., M.C.M., M.R.L., and G.G. performed the research, contributed to patient enrollment and assessment, and collected the data; R.S. performed the research and contributed to the analytical tools; and G.B.M. and G.M. contributed to the design of the research and wrote the paper.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
References
Obermair A, Handisurya A, Kaider A, et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;15: 726-731.
Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28: 1-6.
Nowrousian MR, Kasper C, Oberhoff C. Pathophysiology of cancer-related anemia. In: Smythe J, ed. RHu erythropoietin in Cancer Supportive Treatment. New York, NY: Marcel Dekker; 1996: 13-34.
Spivak JK. The blood in systemic disorders. Lancet. 2000;355: 1707-1712.
Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25: 888-895.
Andrews NC. Disorders of iron metabolism. N engl J Med. 1999;341: 1986-1995.
erslev AJ. Anemia of chronic disease. In: Beutler e, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill Professionals; 2000: 481-488.
Mantovani G, Macciò A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002;98: 84-91.
Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78: 554-561.
Mantovani G, Macciò A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med. 2001;79: 406-414.
Mantovani G, Macciò A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 1997;71: 724-731.
Macciò A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69: 248-252.
Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19: 21-26.
Means RT Jr. The anemia of infection. Baillieres Best Pract Res Clin Haematol. 2000;13: 151-162.
Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100: 3776-3781.
Oken MM, Creech RH., Tormey DC, et al. Toxicity and response criteria of the eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.
Alberti A, Bolognini L, Macciantelli D, et al. The radical cation of N, N-Diethyl-para-Phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed. 2000;26: 253-267.
Cornelli U, Terranova R, Luca S, et al. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr. 2001;131: 3208-3211.
Means RT. Hepcidin and anaemia. Blood Rev. 2004;18: 219-225.
van der Zee AG, de Cuyper eM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75: 1004-1009.
ershler WB. Biological interaction of aging and anemia: a focus on cytokines. J Am Geriatr Soc. 2003;51: S18-S21.
Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113: 1251-1253.
Nemeth e, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113: 1271-1276.
Nemeth e, Valore eV, Territo M, et al. Hepcidin: a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101: 2461-2463.
Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11: 251-254.
Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant. 2004;19: 521-524.
Rivera S, Liu L, Nemeth e, Gabayan V, Sorensen Oe, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. Prepublished on October 12, 2004, as DOI 10.1182/blood-2004-08-3375. (Now available as Blood. 2005;105: 1797-1802).
Nash MA, Ferrandina G, Gordinier M, et al. The role of cytokines in both the normal and the malignant ovary. endocr Relat Cancer. 1999;6: 93-107.
Berek JS, Chung C, Kald K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164: 1038-1042.
Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71: 354-356.
Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med. 1995;73: 409-416.
Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13: 32-37.
Kuzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92: 1684-1688.
Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients whit the anemia of cancer. N engl J Med. 1990;322: 1689-1692.
Alvarez-Hernandez X, Liceaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest. 1989;61: 319-322.
Rogers JT. Ferritin translation by interleukin-1 and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996;87: 2525-2537.
Konijn AM, Carmel N, Levy R, et al. Ferritin synthesis in inflammation: mechanisms of increased ferritin synthesis. Br J Hematol. 1981;49: 361-370.
Denz H, Huber P, Landmann R, et al. Association between the activation of macrophages, changes of iron metabolism and the degree of anemia in patients with malignant disorders. eur J Haematol. 1992;48: 244-248.
Mantovani G, Macciò A, Madeddu C, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003;37: 213-223.
Numcke I, Schneider B, Fandrey J, et al. effect of pro- and antioxidative compounds on renal production of erythropoietin. endocrinology. 1999;140: 641-645.
Takeda A, Toda T, Shinohara S, et al. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40: 104-109.
Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A. 1996;93: 14564-14568.
Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol. 2003;23: 837-843.
Tchekmedian NS. Anemia in cancer patients: significance, epidemiology and current therapy. Oncology. 2002;16: 17-24.
Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003;18: 7-22.(Antonio Macciò, Clelia Ma)